In the second Alessi et al. analysis with single-agent ICIs or an ICI combination with CTLA-4, co-mutated NSCLC patients had significantly worse OS compared with NSCLC patients with SMARCA4 WT/KRAS mutations (3 months versus 15.1 months, HR: 0.29; p < 0.001) [21]. This evidence concerns the gene SMARCA4 and non-small cell lung carcinoma.